Episode Details
Back to EpisodesTrump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors
Published 2 days, 6 hours ago
Description
Water Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-try expansion to federal funding and ibogaine pathway clearance. Sassoon explains what the order gets right, where it falls short (namely on reimbursement and rescheduling), and which companies — including Compass Pathways, Dephinium Therapeutics, and Helus Pharma — stand to benefit most as the sector gains its first clear federal endorsement as a legitimate therapeutic class.